Merck MRK reported first-quarter 2025 adjusted earnings per share (EPS) of $2.22, which beat the Zacks Consensus Estimate of ...

Merck maintained its 2025 full-year revenue guidance of $64.1 billion to $65.6 billion, representing 1% to 3% growth excluding foreign exchange impacts. EPS guidance was adjusted to $8.82 to $8.97, ...

MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.

Proquad is rarely a newsmaker from Merck’s earnings, but this time around, the U.S. has had a series of measles outbreaks.

Merck (MRK) stock trades flat as the company lowers earnings outlook amid tariff impact, even as its Q1 2025 results beat ...

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid an escalating trade war between ...

On an earnings call in February, he answered question after question about plunging demand for his company’s vaccine against ...

Under direction of Health Secretary Robert F. Kennedy Jr., the CDC is considering changes to its recommendations on vaccines ...

United States-based global pharmaceutical company MSD said on Monday that China's National Medical Products Administration has approved the use of multiple new indications of Gardasil®9, its ...

On top of that, trust in vaccines has eroded. Health officials warn the situation is primed to get worse. Recent cuts by the Trump administration have pulled billions of dollars in COVID-19 ...

ripped through communities sprawling across more than 20 Texas counties in part because health departments were starved of the funding needed to run vaccine programs, officials say.

(AP Photo/Julio Cortez, File) Health department staff members enter the Andrews County Health Department measles clinic carrying doses of the measles, mumps and rubella vaccine, Tuesday ...